HIV And Cancer Patients Not Abusing THC-Derived Drug, Researchers Say
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




HIV And Cancer Patients Not Abusing THC-Derived Drug, Researchers Say

CHICAGO, IL -- June 18, 1998 -- San Francisco researchers evaluating clinicians' experiences with Unimed Pharmaceuticals, Inc.’s Marinol(R) (dronabinol) found no observed cases of abuse among patients, confirming its safety in the treatment of appetite loss in people with HIV and vomiting and nausea in people with cancer.

Study findings were presented today by Sarah Calhoun, president and research director, Haight Ashbury Free Clinics, Inc., San Francisco, in conjunction with the College of Problems of Drug Dependency's annual scientific meeting being held in Scottsdale, AZ.

Marinol is the only legally-available synthetic form of THC, the primary psychoactive component present in Cannabis sativa L. (marijuana). The new Marinol study, which was conducted nation-wide over a nine-month period, included the collection of experiences among researchers, physicians, addiction medicine specialists and law enforcement personnel.

"This study can help allay the fears of some clinicians and patients who may be worried about the dangers of using a product like Marinol," Calhoun said. "We feel this product has very low abuse potential."

Among the findings:
-- There is no evidence of Marinol substance abuse or diversion (transferring from legal to illegal channels)
-- Marinol use remains within the therapeutic dosage range over time
-- Cannabis-dependent populations have demonstrated no interest in abuse of Marinol
-- Based on information gathered from law enforcement officials in major cities throughout the United States, there is no street market for Marinol and no evidence of any diversion of Marinol for sale as a street drug
-- Marinol does not provide effects that are considered desirable in a drug of abuse

More information on: Marinol, Unimed Pharmaceuticals, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities